Atea Pharmaceuticals (AVIR) Stock: Buy, Sell, or Hold?
AVIR - Atea Pharmaceuticals, Inc. Common Stock
$4.09
0.00 (0.12%)
▲
5d:
-9.82%
30d:
-22.63%
90d:
-13.64%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When AVIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AVIR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: AVIR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: AVIR is currently trading at $4.08, which is considered oversold relative to its 30-day fair value range of $4.60 to $5.39.
Technical Outlook: Technically, AVIR is in a uptrend. The price is currently testing key support at $4.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AVIR scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.42 (+130.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AVIR is in a uptrend. The price is currently testing key support at $4.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AVIR scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.42 (+130.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.60 -
$5.39
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.8% below Wall St target ($9.42)
- CAUTION: Bottoming setup, but lagging the sector by 15% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-9.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$4.60 -
$5.39
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.51
(12.6%)
Support & Resistance Levels
Support Level
$4.05
Resistance Level
$5.23
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.76
Wall Street Target
$9.42
(+130.8%)
Revenue Growth (YoY)
295.2%
Earnings Growth (YoY)
264.1%
Share & Embed Analysis
Last updated: October 22, 2026 10:01 AM ET
Data refreshes hourly during market hours. Next update: 11:01 AM
Data refreshes hourly during market hours. Next update: 11:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 47 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 71 BUY |